ArticleNeuro-oncology2019
Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Article in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 10 syntheses or guidelines pooled it.
- Radiomics-based artificial intelligence models in brain tumors: A systematic review and meta-analysis of diagnostic performance.Neuroradiology · 2026Pooled it
- Artificial intelligence algorithms for differentiating pseudoprogression from true progression in high-grade gliomas: A systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Radiomics for differentiating radiation-induced brain injury from recurrence in gliomas: systematic review, meta-analysis, and methodological quality evaluation using METRICS and RQS.European radiology · 2025Pooled it
- Systematic review and epistemic meta-analysis to advance binomial AI-radiomics integration for predicting high-grade glioma progression and enhancing patient management.Scientific reports · 2025Pooled it
- Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review.Journal of neuro-oncology · 2023Pooled it
- Machine learning imaging applications in the differentiation of true tumour progression from treatment-related effects in brain tumours: A systematic review and meta-analysis.Journal of medical imaging and radiation oncology · 2022Pooled it
- Discriminators of pseudoprogression and true progression in high-grade gliomas: A systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Imaging Biomarkers of Glioblastoma Treatment Response: A Systematic Review and Meta-Analysis of Recent Machine Learning Studies.Frontiers in oncology · 2022Pooled it
- Pooled it
- Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics.European journal of nuclear medicine and molecular imaging · 2019Pooled it
- Radiomics in glioblastoma recurrence: advances in prediction, localization, and differentiation from treatment-related effects.Journal of translational medicine · 2026Review
- Intratumoral and peritumoral radiomics for the pretreatment prediction of response to neoadjuvant chemotherapy in rhabdomyosarcoma: a multicenter retrospective cohort study.Insights into imaging · 2026Article
- Calibrated and explainable multiparametric MRI radiomics for differentiating tumor positive disease from treatment-related changes in glioblastoma.Frontiers in oncology · 2026Article
- Timepoint-Specific Benchmarking of Deep Learning Models for Glioblastoma Follow-Up MRI.Cancers · 2025Article
- Differentiating tumor recurrence and pseudoprogression in postoperative gliomas using pseudo-continuous arterial spin labeling (pCASL) technique.BMC medical imaging · 2025Article
- Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors.Journal for immunotherapy of cancer · 2025Article
- Predicting Remaining Survival of Glioblastoma Patients with Radiomics Analysis Based onCancers · 2025Article
- Emerging Trends in Artificial Intelligence in Neuro-Oncology.Current oncology reports · 2025Review
- Clinical outcome and deep learning imaging characteristics of patients treated by radio-chemotherapy for a "molecular" glioblastoma.The oncologist · 2025Article
- Multi-modal radiomics model based on four imaging modalities for predicting pathological complete response to neoadjuvant treatment in breast cancer.BMC cancer · 2025Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudoprogression is a diagnostic challenge in early posttreatment glioblastoma. We therefore developed and validated a radiomics model using multiparametric MRI to differentiate pseudoprogression from early tumor progression in patients with glioblastoma.
methodsThe model was developed from the enlarging contrast-enhancing portions of 61 glioblastomas within 3 months after standard treatment with 6472 radiomic features being obtained from contrast-enhanced T1-weighted imaging, fluid-attenuated inversion recovery imaging, and apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) maps. Imaging features were selected using a LASSO (least absolute shrinkage and selection operator) logistic regression model with 10-fold cross-validation. Diagnostic performance for pseudoprogression was compared with that for single parameters (mean and minimum ADC and mean and maximum CBV) and single imaging radiomics models using the area under the receiver operating characteristics curve (AUC). The model was validated with an external cohort (n = 34) imaged on a different scanner and internal prospective registry data (n = 23).
resultsTwelve significant radiomic features (3 from conventional, 2 from diffusion, and 7 from perfusion MRI) were selected for model construction. The multiparametric radiomics model (AUC, 0.90) showed significantly better performance than any single ADC or CBV parameter (AUC, 0.57-0.79, P < 0.05), and better than a single radiomics model using conventional MRI (AUC, 0.76, P = 0.012), ADC (AUC, 0.78, P = 0.014), or CBV (AUC, 0.80, P = 0.43). The multiparametric radiomics showed higher performance in the external validation (AUC, 0.85) and internal validation (AUC, 0.96) than any single approach, thus demonstrating robustness.
conclusionsIncorporating diffusion- and perfusion-weighted MRI into a radiomics model improved diagnostic performance for identifying pseudoprogression and showed robustness in a multicenter setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.